Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 25, 2022

View Archived Issues

Redox-tuned [18F]4FN radiopharmaceutical is useful for imaging innate immunity activation

Evaluating effect of LyeTxI-b on colorectal cancer using chicken chorioallantoic membrane model

Bayer and collaborators patent CSNK1 inhibitors

Foghorn Therapeutics divulges new PROTACs

Jazz Pharmaceuticals synthesizes new Raf kinase inhibitors

Beijing Jacobio Pharmaceuticals presents new glutaminase inhibitors

Chinese investigators identify new PI3Kdelta inhibitors

Osteocytic Cx43 hemichannels as new therapeutic target for treating bone loss and osteoporosis

GI Innovation and CellKey sign biomarker joint research MoU

LABP-66 shows promise for the treatment of multiple sclerosis

VK-1727 reduces EBV proliferation in cells from patients with multiple sclerosis

Lung microbiome affects brain immune cells

Targeting HNRNPA1 effective for treating multiple sclerosis-associated neurodegeneration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...